Brady Lee Stein

Medicine & Life Sciences

1. Primary Myelofibrosis 100%
2. Polycythemia Vera 97%
3. Neoplasms 37%
4. Thrombosis 33%
5. Essential Thrombocythemia 29%
6. Janus Kinase Inhibitors 26%
7. Thrombocytosis 25%
8. Interferons 23%
9. INCB018424 20%
10. Therapeutics 20%
11. Mutation 19%
12. Myelodysplastic Syndromes 17%
13. Megakaryocytes 13%
14. Hydroxyurea 12%
15. Acute Myeloid Leukemia 12%
16. Practice Guidelines 11%
17. Aurora Kinase A 10%
18. Splenomegaly 10%
19. Hemorrhage 10%
20. Philadelphia Chromosome 10%
21. Budd-Chiari Syndrome 10%
22. Transjugular Intrahepatic Portasystemic Shunt 10%
23. Fibrosis 9%
24. Observational Studies 9%
25. Guidelines 9%
26. Antineoplastic Agents 8%
27. Polycythemia 8%
28. Viscera 8%
29. Alleles 8%
30. Anemia 8%
31. Imatinib Mesylate 8%
32. Blood Vessels 7%
33. Genes 7%
34. Veins 7%
35. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 7%
36. Leukocytosis 7%
37. Quality of Life 6%
38. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6%
39. Janus Kinase 2 6%
40. MLN 8237 6%
41. Autophagy-Related Protein-1 Homolog 6%
42. ferric carboxymaltose 6%
43. Portal Hypertension 6%
44. MK 2206 5%
45. platelet protein P47 5%
46. Hematopoiesis 5%
47. Splenic Infarction 5%
48. Interferon Type I 5%
49. Thrombocytopenia 5%